NASDAQ · CELC
Celcuity Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CELC: Nov 05, 2026
Celcuity Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.47. The reported EPS for the same quarter last year was $-0.92.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.47 | $-1.29 | $-1.75 | 4 |
| Dec 2026 | $-0.98 | $-0.68 | $-1.31 | 4 |
| Mar 2027 | $-1.14 | $-1.03 | $-1.26 | 2 |
| Jun 2027 | $-1.04 | $-0.89 | $-1.19 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · The Motley Fool · RTTNews- Fintel · Oct 22, 2:48 PM EDTCantor Fitzgerald Initiates Coverage of Celcuity with Overweight RatingFintel reports that on October 22, 2026, Cantor Fitzgerald initiated coverage of Celcuity (NASDAQCM:CELC) (DB:7VR) with a Overweight recommendation.Prior to this rating action, Celcuity's stock closed at $61.56 on October 21, 2026. The stock has experienced a price change of +2.7
- Zacks · Oct 14, 4:02 AM EDTNew Strong Sell Stocks for October 14thADDYY, CELC and CNL have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2026.
- The Motley Fool · Sep 30, 5:41 PM EDTWhy Celcuity Stock Was a Winner on WednesdayThis is a breast cancer treatment, Revtorpyk.
- RTTNews · Aug 26, 9:28 AM EDTCelcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer(RTTNews) – Celcuity Inc. (CELC) announced that it has submitted a supplemental New Drug Application to the U.S. FDA seeking approval for REVTORPYK for patients with hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation, fol
- The Motley Fool · Aug 20, 5:14 PM EDTCelcuity (CELC) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 13, 7:04 PM EDTCelcuity Q2 Earnings Call Highlights3 Stocks You’ll Wish You Bought Before 2026Celcuity (NASDAQ:CELC) said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval. T
- NASDAQ.com · Aug 13, 2:00 PM EDTAfter-Hours Earnings Report for August 13, 2026 : AMAT, BAP, BLTE, CELC, HTFL, NKTR, DLO, STNE, TMC, GLOB, JCAP, ETONThe following companies are expected to report earnings after hours on 08/13/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Applied Materials, Inc. (AMAT)is reporting for the quarter ending July 31, 2026. The electric company company's consensus
- Zacks · Jul 21, 1:27 PM EDTWhy CELC Stock Declined 15% in a Week Despite a Major FDA WinCelcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
- RTTNews · Jul 18, 1:19 AM EDTWeekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data(RTTNews) – This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks.
- MarketBeat · Jul 15, 4:02 AM EDTCelcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer3 Stocks You’ll Wish You Bought Before 2026Celcuity (NASDAQ:CELC) said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the company’s transition to a commercial-stag
- RTTNews · Jul 15, 1:26 AM EDTCelcuity Wins FDA Approval For REVTORPYK For The Treatment Of Advanced Or Metastatic Breast Cancer(RTTNews) – Celcuity Inc. (CELC), a biotechnology company, announced that the U.S. Food and Drug Administration has approved REVTORPYK (gedatolisib) for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) local
- RTTNews · Jul 1, 6:00 AM EDTBiotech Stocks Facing FDA Decision In July 2026(RTTNews) – July is here, and the FDA is set to announce decisions on therapies for conditions ranging from breast cancer and IgA nephropathy to multiple myeloma, ADHD, and wet AMD.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Celcuity Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.